Evidence map›Paper›PMID 39969500›Full record

ArticleChembiochem : a European journal of chemical biology2025

Mitochondria-Targeted Temozolomide Probe for Overcoming MGMT-Mediated Resistance in Glioblastoma.

Daniel Szames, Shana O Kelley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Role of non-coding RNAs in OOncology letters · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel SzamesDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, Canada.
Shana O KelleyDepartment of Chemistry, Department of Biomedical Engineering, Department of Biochemistry and Molecular Genetics, Northwestern University, 2190 Campus Drive, Evanston, IL, United States.ORCID https://orcid.org/0000-0003-3360-5359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Temozolomide (Tmz) is a DNA methylating agent used for the treatment of glioblastoma multiforme (GBM). Resistance to Tmz in GBM is caused by the DNA direct repair enzyme O

Indexed as

Antineoplastic Agents, AlkylatingDNA Repair EnzymesDrug CarriersGlioblastomaTemozolomideAlkylationDNA, MitochondrialDrug DesignHeLa CellsHumansMitochondriaMolecular ProbesAntineoplastic Agents, AlkylatingDNA, MitochondrialDNA Repair EnzymesDrug CarriersMolecular ProbesTemozolomideDNA DamageGlioblastomaMitochondriaPeptideTemozolomide

Identifiers

PMID39969500
PMCPMC11907389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.